SCHEMBL5196861

SCHEMBL5196861

O=C(O)c1ccc2c(C3CCCCC3)c(-c3ccc4nc(-c5ccccc5F)ccc4c3)n(CC(=O)N3CCOCC3)c2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 3/20 0.39
PRKCA P17252 1/20 0.39
MMP12 P39900 1/20 0.39
HRH1 P35367 1/20 0.38
NR1I2 O75469 1/20 0.37
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
BRD4 O60885 1/20 0.36
CREBBP Q92793 1/20 0.36
SMO Q99835 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HIF1A Q16665 1/20 0.35
ALOX5AP P20292 1/20 0.35
FEN1 P39748 1/20 0.35
TP53 P04637 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
SCN9A Q15858 1/20 0.34
GLP1R P43220 1/20 0.34
MTOR P42345 1/20 0.34
NPC1 O15118 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5227324 0.93 HRH1 (0.37) GRIN2BPRKCAMMP12HRH1NR1I2
SCHEMBL5197903 0.92 PRKCA (0.41) GRIN2BPRKCAMMP12HRH1NR1I2
SCHEMBL5196756 0.92 PRKCA (0.39) GRIN2BPRKCAMMP12HRH1NR1I2
SCHEMBL5197401 0.92 ALDH1A1 (0.39) GRIN2BPRKCAMMP12HRH1NR1I2
SCHEMBL5196408 0.91 PRKCA (0.39) GRIN2BPRKCAMMP12HRH1NR1I2
SCHEMBL5197994 0.91 GRIN2B (0.41) GRIN2BPRKCAMMP12HRH1NR1I2
SCHEMBL5196039 0.91 GRIN2B (0.43) GRIN2BPRKCAMMP12HRH1NR1I2
SCHEMBL5223461 0.91 GRIN2B (0.43) GRIN2BPRKCAMMP12HRH1NR1I2
SCHEMBL5217338 0.90 GRIN2B (0.39) GRIN2BPRKCAMMP12HRH1BRD4
SCHEMBL5197220 0.90 HRH1 (0.41) GRIN2BPRKCAMMP12HRH1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060211698-A1 Bicyclic heteroaryl derivatives for treating viruses GENELABS, INC. 2006-09-21 US claimed
EP-1844042-A1 INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2007-10-17 EP disclosed
US-20060211698-A1 Bicyclic heteroaryl derivatives for treating viruses GENELABS, INC. 2006-09-21 US disclosed
WO-2006076529-A1 INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211698-A1 Bicyclic heteroaryl derivatives for treating viruses HAVCR2, ZC3HAV1, SARS1 GRIN2B 1821/4885PRKCA 4500/4885MMP12 4114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.